Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

The main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.

melanoma skin
malignant melanoma of skin
neutrophil count
thromboplastin
anticoagulants
  • 0 views
  • 29 Apr, 2022
  • 1 location
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

Modulating the gut microbiome to improve response to immune-checkpoint inhibitors is an active area of study. Prebiotic substances (compounds which positively shift the gut microbiome) are a reliable and safe method of gut microbiome modulation. Data suggest that the berry Camu Camu (CC), also known as Myrciaria dubia has prebiotic …

  • 0 views
  • 27 Jul, 2022
  • 1 location
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN)

This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer. Pembrolizumab will be administered every 3 weeks during the neoadjuvant chemotherapy. Tissue and blood samples will be collected pre- and post-treatment for translational research.

cyclophosphamide
erbb2
chromogenic in situ hybridization
metastasis
neutrophil count
  • 7 views
  • 06 Feb, 2022
  • 10 locations
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study

This phase I trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor …

  • 0 views
  • 19 Apr, 2022
  • 1 location
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors

This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab and to compare their differences.

total bilirubin
measurable disease
cancer
solid tumour
ipilimumab
  • 34 views
  • 01 Feb, 2022
  • 1 location
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).

total bilirubin
measurable disease
cancer
durvalumab
ipilimumab
  • 0 views
  • 25 Mar, 2022
  • 1 location
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).

vemurafenib
measurable disease
immunologic adjuvant
immunomodulators
braf v600e mutation
  • 29 views
  • 04 May, 2022
  • 3 locations
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

This open-label phase II trial studies how well niraparib works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The trial is designed to …

  • 14 views
  • 04 Feb, 2022
  • 1 location
Pembrolizumab + Infliximab for Metastatic Melanoma

The purpose of this research is to test the safety and effectiveness of the investigational combination of pembrolizumab and infliximab in treating metastatic melanoma.

  • 0 views
  • 20 Apr, 2022
  • 1 location
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin …

cancer
degarelix
goserelin
leuprolide
endocrine therapy
  • 0 views
  • 20 Apr, 2022
  • 4 locations